Medication info
Rodivica Tablet 5/20 mg (Escitalopram Nicotinate, Olmesartan Medoxomil)

Rodivica Tablet 5/20 mg (Escitalopram Nicotinate, Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
S-Amlodipine Nicotinate›6.506mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Light reddish-brown round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201405619 · Approved 2014.11.28 · Insurance code 645305090

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This drug is administered as 1 tablet once daily with water, regardless of meals. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this drug, it is recommended that the dose be adjusted using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with monotherapy with 2.5 milligrams of S-amlodipine (5 milligrams of amlodipine) or 20 milligrams of olmesartan medoxomil. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with monotherapy with 20 milligrams of olmesartan medoxomil. - 2.5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this drug must not be administered, under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in elderly patients.
Child dose
○ Pediatrics: The safety and efficacy of this drug have not been established in pediatric patients younger than 18 years of age.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication helps effectively manage blood pressure when single therapies do not adequately control blood pressure in patients with essential hypertension by using agents such as Escitalopram (Amlodipine) or Olmesartan Medoxomil together. This stabilizes blood pressure, thereby reducing the risk of cardiovascular complications and improving overall health status. Regular administration by patients is effective for hypertension management.

How to take

Adult dose

This drug is administered as 1 tablet once daily with water, regardless of meals. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this drug, it is recommended that the dose be adjusted using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with monotherapy with 2.5 milligrams of S-amlodipine (5 milligrams of amlodipine) or 20 milligrams of olmesartan medoxomil. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with monotherapy with 20 milligrams of olmesartan medoxomil. - 2.5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this drug must not be administered, under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in elderly patients.

Child dose

○ Pediatrics: The safety and efficacy of this drug have not been established in pediatric patients younger than 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn in the second and third trimesters of pregnancy, so it should be discontinued immediately once pregnancy is confirmed. It should not be used in those with hypersensitivity to any ingredient of this medication, as well as in pregnant or nursing women, patients with severe liver impairment, patients with severe aortic stenosis, patients with biliary obstruction, patients undergoing renal dialysis, patients in shock, or certain diabetic patients. Care should be taken when administering to hypotensive patients who are deficient in body fluids or sodium, as hypotension may occur, and appropriate action should be taken if hypotension develops. Cases of acute vascular dilation leading to excessive drops in blood pressure have been rarely reported; therefore, patients with aortic stenosis should be especially cautious. Use with caution in patients with weakened cardiac function, such as congestive heart failure, or in patients with impaired renal function, as renal function may worsen, requiring close monitoring of their condition. Side effects may include dizziness, headache, hypotension, edema, dyspepsia, rash, etc. If any abnormal symptoms occur, consult a healthcare professional. In particular, pregnant women should consult a doctor if planning to become pregnant or if pregnant, as risks to the fetus may arise. For nursing mothers, it is recommended to stop breastfeeding or discontinue medication because it may be transmitted through breast milk. The safety and efficacy in pediatric patients under 18 years of age have not been established, and usage is not recommended. Elderly patients may have impaired renal and liver function, so they should start with a lower dosage and be administered carefully. Drug interactions may occur when used in combination with other medications, so it is essential to inform healthcare providers about other ongoing treatments, especially avoiding grapefruit juice co-administration. In case of overdose, symptoms may include hypotension and cardiovascular side effects, so care must be taken not to exceed the prescribed dosage, and healthcare professionals should be notified immediately if abnormal symptoms appear. Store the medication out of the reach of children and protect it from moisture, heat, and direct sunlight.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory impairment, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, polyuria, erectile dysfunction, peripheral edema, edema, pitting edema, fatigue, asthenia, facial swelling, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, low back pain, bronchitis, increased creatine kinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, asthenia, angioedema, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute kidney failure, elevated serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, significant hypotension, excessive peripheral vasodilation, tachycardia, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent contamination by air or moisture. It is best kept at room temperature, between 1°C and 30°C, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Light reddish-brown round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.